Purchase this article with an account.
M. E. Cavet, K. Harrington, K. W. Ward, J.-Z. Zhang; Effect of an Investigational Multipurpose Contact Lens Solution on Human Corneal Epithelial Barrier Function. Invest. Ophthalmol. Vis. Sci. 2009;50(13):6355.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To explore in an in vitro setting the effect of an investigational and other commercially available multipurpose contact lens solutions (MPS) on human corneal epithelial barrier structure and function.
Human corneal epithelial cells (HCEpiC) were cultured on collagen coated slides and exposed to an investigational 1 MPS at 50%, 75% and 100% for 30 min. Tight junction structure and integrity were evaluated by confocal microscopy using ZO-1 immunostaining. Quantitative evaluation of barrier function was determined by measuring transepithelial electrical resistance (TEER) across HCEpiC grown on Transwell Clear permeable supports (Costar) at 30, 60 and 120 min after exposure to 50% and 75% MPS. Four commercially available MPS products were also tested, and cell culture media was used as the control.
Overall after exposure to the three concentrations (50%, 75%, and 100%) of the investigational MPS, ZO-1 staining appeared similar to the media control with continuous tight junctions and clear intercellular junctions. At all measured time points after exposure to 50% or 75% investigational MPS there was also no effect on the TEER (p > 0.05 for all time points vs. control, two-way ANOVA-Tukey-Kramer test). In cells exposed to one of the commercially available MPS products there was a dose-dependent change in the distribution of ZO-1 staining and some cell detachment and a decrease in TEER at all time points measured (p < 0.01). To a lesser extent, the remaining three commercial MPS products demonstrated some effects on tight junction ZO-1 distribution and/or TEER.
Based on the in vitro measurements of tight junction protein expression and transepithelial electrical resistance, the investigational MPS did not alter corneal barrier function as compared to control. Differences in epithelial barrier function among the MPSs tested suggest that further study is needed.1-The investigational MPS solution has not been reviewed by the U.S. Food and Drug Administration and no determination of safety or effectiveness of the solution has been made by the agency.
This PDF is available to Subscribers Only